PRO38 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.2368
https://www.valueinhealthjournal.com/article/S1098-3015(19)34746-1/fulltext
Title : PRO38 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34746-1&doi=10.1016/j.jval.2019.09.2368
First page :
Section Title :
Open access? : No
Section Order : 12064
Categories :
Tags :
Regions :
ViH Article Tags :